Post hoc analysis removing all post-QC SCN1A variants showed that the genome-wide burden was not biassed by the enrichment of both the SUDEP and the epilepsy cohorts with Dravet Syndrome patients bearing SCN1A mutations (comparison against epilepsy controls: P = 6.3 × 10− 3; disease controls: P = 1.4 × 10− 3). Here, SCN1A is linked to epilepsy.